CN107383016A - The preparation and application of the Pyrrolopyrimidine compounds of the structure containing heteroaryl amide - Google Patents

The preparation and application of the Pyrrolopyrimidine compounds of the structure containing heteroaryl amide Download PDF

Info

Publication number
CN107383016A
CN107383016A CN201710593543.2A CN201710593543A CN107383016A CN 107383016 A CN107383016 A CN 107383016A CN 201710593543 A CN201710593543 A CN 201710593543A CN 107383016 A CN107383016 A CN 107383016A
Authority
CN
China
Prior art keywords
phenyl
methyl
oxy
carboxamide
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710593543.2A
Other languages
Chinese (zh)
Inventor
郑鹏武
朱五福
唐启东
王林啸
徐珊
兰洲
欧阳宜强
段永丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Science and Technology Normal University
Original Assignee
Jiangxi Science and Technology Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Science and Technology Normal University filed Critical Jiangxi Science and Technology Normal University
Publication of CN107383016A publication Critical patent/CN107383016A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to the Pyrrolopyrimidine compounds and its pharmaceutically acceptable salt of the structure containing heteroaryl amide shown in formula I, hydrate, solvate and prodrug, wherein substituent R1、R2There is the implication provided in the description with Z.There is strong suppression c Met kinases the invention further relates to the compound of formula I, and further relate to such compound and its pharmaceutically acceptable salt, hydrate, solvate or prodrug and preparing treatment due to the purposes in the medicine of c Met kinases overexpression diseases caused, the particularly purposes in the medicine for the treatment of and/or pre- anti-cancer is prepared.

Description

Preparation and application of pyrrolopyrimidine compound containing heteroaryl amide structure
Technical Field
The invention relates to a preparation method of a novel pyrrolopyrimidine compound and a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and application of the compound in preparation of medicines for treating and/or preventing cancers.
Background
Malignant tumors are a disease that seriously jeopardizes human health and life. Human malignancies cause mortality second to cardiovascular, ranked second. About 1000 million tumor patients are diagnosed worldwide each year, 700 million people die from the related diseases caused by tumors, and about 180 million people die from cancers in China each year, which accounts for 1/4 worldwide.
The c-Met kinase is a hepatocyte growth factor receptor and is one of tyrosine kinase receptor family members, and the human c-Met gene is located in the long arm of chromosome 7 (7q31), is about 110kb and contains 21 exons. Mature c-Met consists of a heterodimer of 5.0X 104 alpha subunit and 1.4X 105 beta subunit, the extracellular domain is the alpha chain, the intracellular domain is the beta chain, and the two chains are connected by a disulfide bond. Phosphorylation of Tyr1234 and Tyr1235 in the activation region activates c-Met kinase.
c-Met kinase is widely present in epithelial tissues and plays an important role in embryonic development and wound healing. Recent studies have shown that c-Met kinase exhibits abnormally high expression, mutation or altered activity in tumor tissues such as lung cancer, colon cancer, liver cancer, rectal cancer, gastric cancer, renal cancer, ovarian cancer, glioma, melanoma, breast cancer, prostate cancer and the like. The c-Met kinase can promote the proliferation of tumor cells, regulate the migration of the tumor cells, enhance the invasion capacity of the tumor cells and induce the generation of tumor new vessels.
At present, c-Met kinase has become an important target for research of antitumor drugs. Kim, k.s.; zhang, l.p.; schmidt, R; et a1.discovery of Pyroloridine-pyridine based inhibition of Met Kinase Synthesis, X-ray crystallography Analysis, and biological Activities.j.Med.chem.2008,51, 5330-; cai, z.w.; wei, D.; schroeder, g.m.; the synthesis and pharmacological activity research of a series of pyrrolopyridine compounds shown in the following chemical formulas are reported in the literature of eta1.discovery of organic active pyrazolidine-and aminopyridine-based restriction of biology. Med. chem. Lett.,2008,18, 3224-3229 and the like, and the c-Met kinase inhibitor containing the pyrrolopyridine structure has obvious inhibitory effect on malignant tumors.
In order to develop a novel high-efficiency anti-tumor drug, the inventor conducts extensive research on the pyrrolopyridine compound, modifies and reforms a plurality of structural sites, and synthesizes a series of pyrrolopyrimidine derivatives with novel structures. In vitro antitumor activity screening tests show that the compounds have antitumor activity.
Disclosure of Invention
The invention relates to a pyrrolopyrimidine compound containing a heteroaryl amide structure and shown as a general formula I, and a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.
Wherein
R1Is hydrogen, (C)1-C6) Alkyl, aryl, heteroaryl, and heteroaryl,
R21-4 same or different hydrogen, fluorine, bromine and iodine;
y is O, S;
z is-Ar1-Ar2；
Ar1、Ar2Is a five-or six-membered heteroaryl group, the heteroaryl group containing 1-3 heteroatoms such as N, O, S, Ar1And Ar2Are connected to and Ar2And optionally further substituted by 1 to 3 identical or different R5Substitution;
n is 1 to 3;
R3、R4the same or different, and the same or different,are each independently selected from (C)1-C6) Alkyl, (C)3-C6) A cycloalkyl group; or R3And R4Together with the nitrogen atom to which they are attached form a 5-10 membered saturated heterocyclic group, except that R3And
R4optionally containing 1 to 3 heteroatoms selected from O, N and S in addition to the attached nitrogen atom.
R51 to 3 same or different hydrogen, halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, amino, azido, nitro, cyano, mercapto, (C)1-C4) Alkyl, (C)3-C6) Cycloalkyl group, (C)1-C4) Alkenyl, (C)1-C4) Alkynyl, (C)1-C4) Alkoxy group, (C)1-C4) Alkylthio, allyl, (2-methyl) allyl, (C)1-C4) Alkoxymethyl group, (C)1-C4) Alkyl acyl group, (C)1-C3) A substituent of an alkylenedioxy group.
The present invention preferably also relates to compounds of the general formula I as defined below, or racemates or optical isomers thereof, or pharmaceutically acceptable salts and/or hydrates thereof,
wherein,
R1is hydrogen, methyl, ethyl,
Is composed of
n is 2 and 3;
R21-4 same or different hydrogen and fluorine;
y is O;
z is
R51 to 3 identical or different substituents selected from the group consisting of hydrogen, fluorine, chlorine, bromine, hydroxyl, trifluoromethyl, trifluoromethoxy, amino, azido, nitro, cyano, mercapto, methyl, ethyl, n-propyl, cyclopropyl, tert-butyl, vinyl, propenyl, 2-methylpropenyl, ethynyl, methoxy, ethoxy, cyclopropoxy, tert-butoxy, methylthio, ethylthio, allyl, (2-methyl) allyl, methoxymethyl, ethoxymethyl, isopropoxymethyl, formyl, acetyl, propionyl, cycloproponyl, butyryl, 2, 3-methylenedioxy, 2, 3-ethylenedioxy.
Very particular preference is given according to the invention to the following derivatives of the general formula I, including racemates or optical isomers thereof, and pharmaceutically acceptable salts and/or hydrates thereof, without these compounds being intended to restrict the invention in any way:
(1) n- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(2) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3, 4-difluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(3) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (4-chlorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(4) N- (4- ((7H-phenyl [2,3-d ] pyrimidine-4-yl) oxy) phenyl-1- (4-fluorophenyl) -5-methyl-1H-1, 2, 3-triazole-4-carboxamide
(5) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5-methyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(6) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(7) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(8) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (3, 4-difluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(9) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (4-chlorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(10) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (4-fluorophenyl) -5-methyl-1H-1, 2, 3-triazole-4-carboxamide
(11) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -5-methyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(12) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(13)1- (3-chloro-4-fluorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(14)1- (3, 4-difluorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(15)1- (4-chlorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(16)1- (4-fluorophenyl) -5-methyl-N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1H-1, 2, 3-triazole-4-carboxamide
(17) 5-methyl-N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidine-4-yl) oxy) phenyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(18) N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(19)1- (3-chloro-4-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(20)1- (3, 4-difluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(21)1- (4-chlorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(22)1- (4-fluorophenyl) -5-methyl-N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1H-1, 2, 3-triazole-4-carboxamide
(23) 5-methyl-N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(24) N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(25) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(26) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(27) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(28) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(29) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-bromo-2-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(30) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (3- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(31) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(32) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(33) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(34) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(35) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-bromo-2-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(36) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (3- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(37) 4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(38)1- (4-bromo-2-fluorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
(39)1- (3-fluorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
(40) 4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(41) 4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1- (2- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(42)1- (2-chlorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
(43) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(44)1- (4-bromo-2-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(45) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(46) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(47) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(48)1- (2-chlorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(49) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (4-methyl) -1, 4-dihydropyridazine-3-carboxamide
(50) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 4-dihydropyridazine-3-carboxamide
(51)1- (4-bromo-2-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1, 4-dihydropyridazine-3-carboxamide
(52) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (3- (trifluoromethyl) phenyl) -1, 4-dihydropyridazine-3-carboxamide
(53) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (3- (trifluoromethyl) phenyl) -1, 4-dihydropyridazine-3-carboxamide
Furthermore, the pyrrolopyrimidine compounds of general formula I containing a heteroaryl amide structure of the present invention may be used with an acid to form pharmaceutically acceptable salts thereof according to conventional methods in the art to which the present invention pertains. The acid may include inorganic or organic acids, and salts with the following acids are particularly preferred: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, tartaric acid, benzenesulfonic acid, benzoic acid, p-toluenesulfonic acid, and the like.
In addition, the present invention also includes prodrugs of the compounds of the present invention. Prodrugs, according to the present invention, are derivatives of compounds of formula i which may themselves have poor or even no activity, but which, upon administration, are converted under physiological conditions (e.g., by metabolism, solvolysis or otherwise) to the corresponding biologically active form.
The term "halo" as used herein, unless otherwise indicated, refers to fluoro, chloro, bromo or iodo; "alkyl" refers to straight or branched chain alkyl; "cycloalkyl" refers to a substituted or unsubstituted cycloalkyl; "alkenyl" means straight or branched chain alkenyl; "alkynyl" refers to straight or branched chain alkynyl groups; "aryl" refers to an organic group obtained by removing one hydrogen atom from an aromatic hydrocarbon, such as phenyl, naphthyl; 5-to 10-membered heteroaryl includes those containing one or more heteroatoms selected from N, O and S, wherein the ring system of each heteroaryl group may be monocyclic or polycyclic, the ring system is aromatic, and contains a total of 5 to 10 atoms, and examples thereof include imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, (1,2,3) -and (1,2,4) -triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, benzothienyl, benzofuryl, benzimidazolyl, benzothiazolyl, indolyl, quinolyl and the like; 5-10 membered heterocyclic groups include those containing one or more heteroatoms selected from N, O and S, wherein the ring system of each heteroaryl group may be monocyclic or polycyclic but is non-aromatic, the ring system containing a total of 5 to 10 atoms and may optionally include 1 or 2 carbon-carbon double or triple bonds, and there may be mentioned, for example, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, thiazolinyl and the like.
The invention also relates to a compound with a general formula I, which has a strong effect of inhibiting c-Met kinase, and also relates to application of the compound and pharmaceutically acceptable salts and hydrates thereof in preparing medicines for treating diseases caused by abnormal high expression of c-Met kinase, in particular to application in preparing medicines for treating and/or preventing cancers.
The following schemes 1-4 describe the preparation of the compounds of formula I of the present invention, all starting materials are prepared by the methods described in these schemes, by methods well known to those of ordinary skill in the art of organic chemistry or are commercially available. All of the final compounds of the present invention are prepared by the methods described in these schemes or by methods analogous thereto, which are well known to those of ordinary skill in the art of organic chemistry. All of the variables used in these schemes are as defined below or in the claims.
According to the invention, the compounds of the formula I, Z isY、R1、R2、R5As defined in the summary section, the process according to scheme 1.1 can be carried out from intermediate A and intermediate B1Examples 1-24 were prepared by substitution; when Z isY、R1、R2、R5As defined in the summary section, the process according to scheme 1.2 can be carried out from intermediate A and intermediate B2Examples 25-48 were prepared by substitution; z isY、R1、R2、R5As defined in the summary section, the process according to scheme 1.3 can be carried out from intermediate A and intermediate B3Examples 49-53 were prepared by substitution reactions in a manner analogous to scheme 1.2 and therefore are not described in detail herein.
Route 1.1
Route 1.2
Route 1.3
The compounds of formula I, intermediates A, according to the invention are prepared as in scheme 2, and the other substituents are as defined in the claims.
Route 2
When D is S, compound A can be prepared from the intermediate in scheme 2 and 2-fluoro-4-nitrothiophenol by a two-step reaction of substitution and reduction.
When D is O, compound a can be prepared from the intermediate of scheme 2 by a two step substitution and reduction reaction with 4-nitrophenol.
According to the invention, the compounds of the formula I, when Z isIntermediate B1The process is as in scheme 3, and the other substituents are as defined in the claims.
Route 3
When Z isIntermediate B2The process is as in scheme 3, and the other substituents are as defined in the claims.
Route 4
Substituents R of all intermediates in the four routes above1、R2、R5And Ar2As defined in the claims.
The specific implementation mode is as follows:
the examples are intended to illustrate, but not to limit, the scope of the invention. NMR of the compounds was measured using brukerARX-300 and Mass Spectroscopy was measured using Agilent 1100 LC/MSD; all reagents used were analytically or chemically pure.
The compounds of examples 1-24, 25-48 and 49-53 (see Table I) were prepared according to general preparative methods 1.1, 1.2 and 1.3, respectively.
Table one:
example (1)
N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
Step one 4- (4-Nitrophenyl) -1H-pyrrolo [2,3-d ] pyrimidine (b)
In a 250mL three-necked bottle, diphenyl ether (51.843g, 0.3mol) is preheated to be completely dissolved, then 4-chloro-7H-pyrrolo [2,3-b ] pyrimidine (9.996g, 0.066mol) and 4-nitrophenol (16.862g, 0.107mol) are sequentially added, the temperature is increased to 190 ℃ for reaction for about 1H, a large amount of solid cannot be stirred in the process, the solid is dissolved when the temperature is increased to about 130 ℃, the solution is light yellow, the color of the solution is deepened along with the temperature increase, the appearance is dark brown, and the color of the solution is still light yellow when a sample point is taken. After the reaction solution was cooled, the reaction solution was slowly added dropwise to 400mL of ethyl acetate and stirred for 2 hours, the precipitated solid was filtered by suction, and the filter cake was dried to obtain 8.285g of a yellowish brown powder with a yield of 46.3%.
Step two 4- ((1H-pyrrolo [2,3-d ] pyrimidin-4-yloxy) aniline (A)
Adding the intermediate b (5.102g, 0.0187mol) into ethanol (100mL), sequentially adding ferric trichloride (2.687g, 0.00994mol) and activated carbon (8.440g,0.703mol) under stirring, and dropwise adding hydrazine hydrate (9.445g, 0.1887mol) when the temperature is raised to about 50 ℃. After the completion of the dropwise addition, the temperature was raised to 80 ℃ and the reflux was continued for about 10 min. And cooling the reaction solution, performing suction filtration, performing rotary evaporation on the filtrate, adding 75mL of water after evaporation to dryness, performing ultrasonic treatment to separate out a large amount of yellow solid, performing suction filtration, and drying a filter cake to obtain 2.432g of yellow powder with the yield of 53.6%.
Step Triethyl 5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxylic acid ethyl ester (f)
Dissolving the intermediate f and ethyl 4,4, 4-trifluoro-3-oxobutyrate in 50mL DMSO/H2O (10:1), adding Cu (OAc)2 and Piperidine, reacting at 80 ℃ for 24 hours by a one-pot method, filtering, adding water to precipitate a solid, and performing suction filtration and drying to obtain a yellow solid. The yield thereof was found to be 70%.
Step four 5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H- (1,2, 3-triazole-4-carboxylic acid) (g)
Intermediate e was dissolved in 50mL ethanol over 2N Na2CO3Then, the temperature was raised to 80 ℃ to react for 4 hours. After most of the reaction solution was distilled off, a large amount of water was added, the pH was adjusted to 2 to 3 with 6M dilute hydrochloric acid, and the mixture was concentrated to obtain a yellow solid. The yield thereof was found to be 80%.
Step five 5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carbonyl chloride (B)1)
Intermediate g (0.01mol) was added to 30mL of toluene, and SOCl was added2(6mL) and pyridine (5d) were allowed to warm to 85 ℃ for 6 h. After the reaction mixture was cooled to room temperature, toluene and SOCl were distilled off under reduced pressure2To obtain oily liquid acyl chloride. The yield is 50%
Step Hexa N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide (i)
Intermediate A (0.05g, 0.00021mol) and N, N-diisopropylethylamine (0.5mL, 0.003mol) were added to 10mL of dichloromethane and intermediate B1(0.2g, 0.00059mol) was dissolved in 5mL of dichloromethane, added dropwise to the above dichloromethane solution at 0 ℃ and allowed to slowly warm to room temperature after completion of the addition, and reacted for 1 to 2 hours. After completion of the reaction, 5mL of an 5% aqueous solution of sodium hydroxide was added, stirred for half an hour, transferred to a 250mL separatory funnel, and 25mL of dichloromethane was added, washed three times (50 mL. times.3) with a saturated aqueous solution of sodium carbonate, washed once with a saturated aqueous solution of sodium chloride, and dichloromethane was distilled off under reduced pressure to obtain 0.05g of a pale yellow solid powder with a yield of 46.14%. ES I-MS m/z 519.06;1H NMR(400MHz,DMSO)12.11(s，1H),11.13(s,1H),8.33(s,1H),8.21(dd,J＝6.4,2.4Hz,1H),7.89(d,J＝9.0Hz,2H),7.86–7.83(m,1H),7.76(t,J＝8.9Hz,1H),7.51(d,J＝3.4Hz,1H),7.26(d,J＝8.9Hz,2H),6.51(d,J＝3.4Hz,1H).
according to the method of the embodiment 1, firstly, different substituted triazole acids react to prepare different substituted dihydropyridazine formic acids; then the intermediate A and the intermediate A are reacted according to the method of the seventh step to respectively prepare the compounds of the examples 2 to 28
Example (2)
N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3, 4-difluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:502.10；1H NMR(400MHz,DMSO)12.11(s，1H),11.13(s,1H),8.33(s,1H),8.10(t,J＝7.7Hz,2H),7.80(dd,J＝18.5,9.1Hz,1H),7.72(s,1H),7.51(d,J＝3.4Hz,1H),7.26(d,J＝8.8Hz,2H),6.51(d,J＝3.4Hz,1H).
Example (3)
N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (4-chlorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:501.07；1H NMR(400MHz,DMSO)12.14(s，1H),11.11(s,1H),8.34(s,1H),7.88(d,J＝8.8Hz,2H),7.82–7.74(m,4H),7.51(d,J＝3.3Hz,1H),7.26(d,J＝8.7Hz,2H),6.50(d,J＝3.3Hz,1H).
Example (4)
N- (4- ((7H-phenyl [2,3-d ] pyrimidine-4-yl) oxy) phenyl-1- (4-fluorophenyl) -5-methyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:430.14；1H NMR(400MHz,DMSO)12.21(s，1H),10.78(s,1H),8.45(s,1H),8.03(d,J＝8.9Hz,2H),7.86(dd,J＝8.8,4.9Hz,2H),7.62(dd,J＝10.6,6.8Hz,3H),7.34(d,J＝8.9Hz,2H),6.59(d,J＝3.4Hz,1H),3.93(s,3H),2.60(s,3H).
Example (5)
N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5-methyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:412.15；1H NMR(400MHz,DMSO)12.13(s，1H),10.78(s,1H),8.45(s,1H),8.03(d,J＝8.9Hz,2H),7.76(d,J＝6.9Hz,5H),7.62(d,J＝3.4Hz,1H),7.34(d,J＝8.9Hz,2H),6.59(d,J＝3.5Hz,1H),2.69(s,3H).
Example (6)
N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:534.11；1H NMR(400MHz,DMSO)12.12(s，1H),11.13(s,1H),8.33(s,1H),8.10(t,J＝7.7Hz,2H),7.80(dd,J＝18.5,9.1Hz,1H),7.72(s,1H),7.51(d,J＝3.4Hz,1H),7.26(d,J＝8.8Hz,2H),6.51(d,J＝3.4Hz,1H).
Example (7)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:537.06；1H NMR(400MHz,DMSO)12.10(s，1H),11.26(s,1H),8.27(s,1H),8.16(dd,J＝6.5,2.5Hz,1H),7.88(dd,J＝12.7,2.2Hz,1H),7.83–7.77(m,1H),7.70(dd,J＝16.2,7.7Hz,2H),7.51(d,J＝3.5Hz,1H),7.39(t,J＝8.8Hz,1H),6.58(d,J＝3.5Hz,1H).
Example (8)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (3, 4-difluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:520.10；1H NMR(400MHz,DMSO)12.14(s，1H),11.26(s,1H),8.27(s,1H),8.06(d,J＝10.2Hz,1H),7.88(d,J＝12.8Hz,1H),7.79–7.72(m,1H),7.67(d,J＝6.2Hz,2H),7.51(d,J＝3.5Hz,1H),7.45–7.40(m,1H),6.58(d,J＝3.5Hz,1H).
Example (9)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (4-chlorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:519.07；1H NMR(400MHz,DMSO)12.13(s，1H),11.24(s,1H),8.27(s,1H),7.88(d,J＝12.4Hz,1H),7.73(t,J＝6.4Hz,3H),7.70–7.64(m,2H),7.51(d,J＝3.5Hz,1H),7.39(t,J＝8.9Hz,1H),6.58(d,J＝3.4Hz,1H).
Example (10)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (4-fluorophenyl) -5-methyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:448.14；1H NMR(400MHz,DMSO)12.14(s，1H),10.88(s,1H),8.34(s,1H),7.98(dd,J＝13.0,2.3Hz,1H),7.79–7.72(m,2H),7.56(d,J＝3.5Hz,1H),7.52(dd,J＝11.9,5.5Hz,3H),7.40(t,J＝8.9Hz,1H),6.63(d,J＝3.5Hz,1H),2.56(s,3H).
Example (11)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -5-methyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:430.15；1H NMR(400MHz,DMSO)12.13(s，1H),10.87(s,1H),8.34(s,1H),7.98(dd,J＝13.0,2.2Hz,5H),7.77(d,J＝8.8Hz,1H),7.73–7.61(m,1H),2.58(s,3H).
Example (12)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:552.11；1H NMR(400MHz,DMSO)12.12(s，1H),11.36(s,1H),8.34(s,1H),8.12(dd,J＝14.0,7.4Hz,2H),8.07–7.90(m,3H),7.74(d,J＝8.1Hz,1H),7.56(s,1H),7.46(t,J＝8.8Hz,1H),6.64(d,J＝3.4Hz,1H).
Example (13)
1- (3-chloro-4-fluorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:533.08；1H NMR(400MHz,DMSO)11.13(s,1H),8.33(s,1H),8.21(dd,J＝6.4,2.4Hz,1H),7.89(d,J＝9.0Hz,2H),7.86–7.83(m,1H),7.76(t,J＝8.9Hz,1H),7.51(d,J＝3.4Hz,1H),7.26(d,J＝8.9Hz,2H),6.51(d,J＝3.4Hz,1H),3.82(s,3H).
Example (14)
1- (3, 4-difluorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:516.12；1H NMR(400MHz,DMSO)11.13(s,1H),8.33(s,1H),8.10(t,J＝7.7Hz,2H),7.80(dd,J＝18.5,9.1Hz,1H),7.72(s,1H),7.51(d,J＝3.4Hz,1H),7.26(d,J＝8.8Hz,2H),6.51(d,J＝3.4Hz,1H),3.82(s,3H).
Example (15)
1- (4-chlorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:515.09；1H NMR(400MHz,DMSO)11.11(s,1H),8.34(s,1H),7.88(d,J＝8.8Hz,2H),7.82–7.74(m,4H),7.51(d,J＝3.3Hz,1H),7.26(d,J＝8.7Hz,2H),6.50(d,J＝3.3Hz,1H),3.82(s,3H).
Example (16)
1- (4-fluorophenyl) -5-methyl-N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:444.15；1H NMR(400MHz,DMSO)10.78(s,1H),8.45(s,1H),8.03(d,J＝8.9Hz,2H),7.86(dd,J＝8.8,4.9Hz,2H),7.62(dd,J＝10.6,6.8Hz,3H),7.34(d,J＝8.9Hz,2H),6.59(d,J＝3.4Hz,1H),3.93(s,3H),2.60(s,3H).
Example (17)
5-methyl-N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidine-4-yl) oxy) phenyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:426.16；1H NMR(400MHz,DMSO)10.78(s,1H),8.45(s,1H),8.03(d,J＝8.9Hz,2H),7.76(d,J＝6.9Hz,5H),7.62(d,J＝3.4Hz,1H),7.34(d,J＝8.9Hz,2H),6.59(d,J＝3.5Hz,1H),3.93(s,3H),2.69(s,3H).
Example (18)
N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:548.12；1H NMR(400MHz,DMSO)11.13(s,1H),8.33(s,1H),8.10(t,J＝7.7Hz,2H),7.80(dd,J＝18.5,9.1Hz,1H),7.72(s,1H),7.51(d,J＝3.4Hz,1H),7.26(d,J＝8.8Hz,2H),6.51(d,J＝3.4Hz,1H),3.82(s,3H).
Example (19)
1- (3-chloro-4-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:551.08；1H NMR(400MHz,DMSO)11.26(s,1H),8.27(s,1H),8.16(dd,J＝6.5,2.5Hz,1H),7.88(dd,J＝12.7,2.2Hz,1H),7.83–7.77(m,1H),7.70(dd,J＝16.2,7.7Hz,2H),7.51(d,J＝3.5Hz,1H),7.39(t,J＝8.8Hz,1H),6.58(d,J＝3.5Hz,1H),3.77(s,3H).
Example (20)
1- (3, 4-difluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:534.12；1H NMR(400MHz,DMSO)11.24(s,1H),8.27(s,1H),7.88(d,J＝12.4Hz,1H),7.73(t,J＝6.4Hz,3H),7.70–7.64(m,2H),7.51(d,J＝3.5Hz,1H),7.39(t,J＝8.9Hz,1H),6.58(d,J＝3.4Hz,1H),3.77(s,3H).
Example (21)
1- (4-chlorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:533.09；1H NMR(400MHz,DMSO)11.24(s,1H),8.27(s,1H),7.88(d,J＝12.4Hz,1H),7.73(t,J＝6.4Hz,3H),7.70–7.64(m,2H),7.51(d,J＝3.5Hz,1H),7.39(t,J＝8.9Hz,1H),6.58(d,J＝3.4Hz,1H),3.77(s,3H).
Example (22)
1- (4-fluorophenyl) -5-methyl-N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:462.15；1H NMR(400MHz,DMSO)10.88(s,1H),8.34(s,1H),7.98(dd,J＝13.0,2.3Hz,1H),7.79–7.72(m,2H),7.56(d,J＝3.5Hz,1H),7.52(dd,J＝11.9,5.5Hz,3H),7.40(t,J＝8.9Hz,1H),6.63(d,J＝3.5Hz,1H),3.83(s,3H),2.56(s,3H).
Example (23)
5-methyl-N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
ESI-MS m/z:444.16；1H NMR(400MHz,DMSO)10.87(s,1H),8.34(s,1H),7.98(dd,J＝13.0,2.2Hz,5H),7.77(d,J＝8.8Hz,1H),7.73–7.61(m,1H),3.83(s,3H),2.58(s,3H).
Example (24)
N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
ESI-MS m/z:566.12；1H NMR(400MHz,DMSO)11.36(s,1H),8.34(s,1H),8.12(dd,J＝14.0,7.4Hz,2H),8.07–7.90(m,3H),7.74(d,J＝8.1Hz,1H),7.56(s,1H),7.46(t,J＝8.8Hz,1H),6.64(d,J＝3.4Hz,1H),3.83(s,3H).
When Z isX、Y、D、R1、R2As defined in the summary section, the process according to scheme 1.2 can be carried out from intermediate A and intermediate B2Examples 25-44 were prepared by substitution reactions.
The preparation methods of the first to second steps are already described in the general method 1, and are not repeated.
Step Tris cis ethyl-3-oxo-2- (4-fluorophenylhydrazono) butanoic acid ethyl ester (g)
A mixed solution of 50mL of water and 200mL of ethanol was added to a 500mL three-necked flask, and after adding anhydrous sodium acetate and stirring until dissolved, ethyl acetoacetate was added and the mixture was stirred at room temperature for 2 hours. Adding aniline and 50mL of water into another 250mL three-necked bottle, dropwise adding concentrated hydrochloric acid at room temperature, dropwise adding an aqueous solution of sodium nitrite when the temperature is reduced to-5 ℃ after the dropwise adding is finished, keeping the temperature of the solution lower than 0 ℃, reacting for 30min at 0 ℃ after the dropwise adding is finished, and supplementing a small amount of water if solids exist in the solution so as to keep the diazonium salt solution clear. Cooling the mixed solution of ethyl acetoacetate to a solution temperature below 0 ℃, installing a mechanical stirrer, slowly dropping the obtained diazonium salt solution, keeping the solution temperature below 0 ℃, generating a large amount of yellow solids in the reaction solution along with the dropping of the diazonium salt solution, supplementing 100mL of water after the dropping is finished, and reacting for 2 hours below 0 ℃. And (3) carrying out suction filtration on the yellow solid obtained in the reaction solution, washing a filter cake with water, and drying. 17g of product was obtained with a yield of more than about 95%.
Step Tetra4-methyl-6-oxo-1- (4-fluorophenyl) -1, 6-dihydropyridazine-3-carboxylic acid ethyl ester (h)
Intermediate g (5g, 0.0166mol), ethoxycarbonylmethylenetriphenylphosphonium (9.39g, 0.027mol) and Et2NH (0.28mL, 0.0027mol) was added to DMSO at room temperature and the temperature was raised to 85 ℃ for 4 h. The intermediate g is not reacted completely. The reaction solution was cooled to room temperature, poured into water, extracted with DCM, and the organic layer was washed with brine three times again and dried over anhydrous sodium sulfate. Filtration with suction and evaporation of DCM to dryness gave a brown oil, in which intermediate g remained. The yield thereof was found to be 78%.
Step five 4-methyl-6-oxo-1- (4-fluorophenyl) -1, 6-dihydropyridazine-3-carboxylic acid (i)
Dissolving the intermediate h in 50mL of ethanol, dropwise adding 10% NaOH at room temperature to adjust the pH value of the solution to 12, and then heating to 60 ℃ for reaction for 4 h. Evaporating most of the reaction solution, adding a large amount of water, extracting the aqueous solution with ethyl acetate, separating the water layer, adjusting the pH value of the water layer to 2-3 with 6M dilute hydrochloric acid, extracting the water layer with DCM, drying the DCM solution with anhydrous sodium sulfate, filtering, and concentrating to obtain a yellow solid. The yield thereof was found to be 70%.
Step Hexa 4-methyl-6-oxo-1- (4-fluorophenyl) -1, 6-dihydropyridazine-3-carbonyl chloride (B)2)
Intermediate i (0.01mol) was added to 30mL of toluene, and SOCl was added2(6mL) and pyridine (5d) were allowed to warm to 85 ℃ for 6 h. After the reaction mixture was cooled to room temperature, toluene and SOCl were distilled off under reduced pressure2To obtain oily liquid acyl chloride. The yield is 50%
Step heptan- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (4-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
Example (25)
Intermediate A (0.05g, 0.00021mol) and N, N-diisopropylethylamine (0.5mL, 0.003mol) were added to 10mL of dichloromethane and intermediate B2(0.2g, 0.00073mol) was dissolved in 5mL of dichloromethane, added dropwise to the above dichloromethane solution at 0 ℃ and allowed to slowly warm to room temperature after completion of the addition, and reacted for 1 to 2 hours. After completion of the reaction, 5mL of an 5% aqueous solution of sodium hydroxide was added, stirred for half an hour, transferred to a 250mL separatory funnel, and 25mL of dichloromethane was added, washed three times (50 mL. times.3) with a saturated aqueous solution of sodium carbonate, washed once with a saturated aqueous solution of sodium chloride, and dichloromethane was distilled off under reduced pressure to obtain 0.05g of a pale yellow solid powder with a yield of 46.14%. ESI-MS 457.141H NMR(400MHz,DMSO)12.55(s,1H),10.73(s,1H),8.89(s,1H),8.57(s,1H),8.23(d,J＝3.5Hz,1H),7.93–7.87(m,2H),7.75(s,1H),7.46(dd,J＝18.1,8.9Hz,3H),7.17(s,1H),6.97(d,J＝3.7Hz,1H),6.89(s,1H),2.51(s,3H).
According to the method of example 1, different substituted dihydropyridazines are first obtained by reaction with different substituted anilines; then the intermediate A and the intermediate A are reacted according to the method of the step eight to respectively prepare the compounds of the examples 26 to 48
Example (26)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (3-fluorophenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
.ESI-MS 457.141H NMR(400MHz,DMSO)12.55(s,1H),10.75(s,1H),8.88(s,1H),8.57(s,1H),8.22(d,J＝3.5Hz,1H),7.90(d,J＝8.6Hz,2H),7.76(d,J＝5.0Hz,1H),7.59–7.47(m,2H),7.43(d,J＝8.9Hz,2H),7.20(s,1H),6.97(d,J＝3.6Hz,1H),2.52(s,3H).
Example (27)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (4-methylbenzene) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 453.161H NMR(400MHz,DMSO)12.45(s,1H),10.61(s,1H),8.79(s,1H),8.13(d,J＝3.6Hz,1H),7.82(d,J＝8.8Hz,2H),7.66(s,1H),7.60(d,J＝8.1 Hz,2H),7.34(d,J＝8.5Hz,3H),7.05(s,1H),6.88(d,J＝3.7Hz,1H),2.41(s,3H),2.39(s,3H).
Example (28)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
.ESI-MS 523.131H NMR(400MHz,DMSO)12.45(s,1H),12.09(s,1H),8.79(s,1H),8.14(d,J＝3.7Hz,1H),7.90(d,J＝7.8Hz,1H),7.83(d,J＝8.8Hz,2H),7.78–7.65(m,3H),7.37(d,J＝8.1Hz,2H),6.89(d,J＝4.0Hz,1H),6.81(s,1H),2.12(s,3H).
Example (29)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (4-bromo-2-fluorophenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 536.041H NMR(400MHz,DMSO)12.45(s,1H),10.65(s,1H),8.79(s,1H),8.13(d,J＝4.0Hz,1H),7.83(dd,J＝17.2,9.6Hz,2H),7.69(dd,J＝15.0,7.5Hz,2H),7.34(d,J＝8.6Hz,2H),7.11(s,1H),6.88(d,J＝3.6Hz,1H),6.80(s,1H),2.43(s,3H).
Example (30)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (3- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 507.131H NMR(400MHz,DMSO)12.45(s,1H),10.57(s,1H),8.26(s,1H),7.70(d,J＝8.7Hz,2H),7.61(d,J＝10.2Hz,1H),7.58–7.46(m,2H),7.43(d,J＝3.1Hz,1H),7.24(t,J＝8.5Hz,1H),7.18(d,J＝8.8Hz,2H),7.01(s,1H),6.39(d,J＝3.3Hz,1H),2.32(s,3H).
Example (31)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (4-fluorophenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
.ESI-MS 457.141H NMR(400MHz,DMSO)12.28(s,1H),10.74(s,1H),8.27(s,1H),7.83(d,J＝12.4Hz,1H),7.77–7.74(m,2H),7.55–7.49(m,2H),7.43(d,J＝8.8Hz,1H),7.36(t,J＝8.7Hz,2H),7.06(s,1H),6.58(s,1H),2.39(s,3H).
Example (32)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (3-fluorophenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 457.14
Example (33)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (4-methylbenzene) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 453.161H NMR(400MHz,CDCl3)12.28(s,1H),10.72(s,1H),8.27(s,1H),7.83(d,J＝12.6Hz,1H),7.57(d,J＝8.1Hz,2H),7.51(d,J＝10.0Hz,2H),7.41(t,J＝8.8Hz,1H),7.32(d,J＝8.1Hz,2H),7.03(s,1H),6.58(s,1H),2.39(s,3H),2.36(s,3H).
Example (34)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 523.131H NMR(400MHz,DMSO)12.28(s,1H),12.15(s,1H),8.85(s,1H),8.28(s,1H),7.92(d,J＝8.5Hz,1H),7.87(d,J＝7.8Hz,1H),7.74(d,J＝8.2Hz,2H),7.68(d,J＝7.9Hz,1H),7.49(d,J＝9.5Hz,2H),7.43(t,J＝8.4Hz,1H),6.59(s,1H),2.09(s,3H).
Example (35)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (4-bromo-2-fluorophenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 535.051H NMR(400MHz,DMSO)12.29(s,1H),10.80(s,1H),8.27(s,1H),7.82(d,J＝10.8Hz,2H),7.72–7.60(m,2H),7.58–7.48(m,2H),7.41(t,J＝8.9Hz,1H),7.09(s,1H),6.57(s,1H),2.40(s,3H).
Example (36)
N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (3- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 507.131H NMR(400MHz,DMSO)12.28(s,1H),10.79(s,1H),8.28(s,1H),8.16(s,1H),8.07(d,J＝7.4Hz,1H),7.88–7.82(m,2H),7.78(t,J＝7.7Hz,1H),7.55–7.49(m,2H),7.43(t,J＝8.8Hz,1H),7.11(s,1H),6.59(s,1H),2.42(s,3H).
Example (37)
4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
.ESI-MS 537.151H NMR(400MHz,DMSO)12.07(s,1H),8.86(s,1H),8.34(s,1H),7.87(d,J＝7.9Hz,1H),7.77(d,J＝8.9Hz,1H),7.72(t,J＝8.4Hz,2H),7.69–7.66(m,1H),7.50(d,J＝3.4Hz,1H),7.26(d,J＝8.8Hz,2H),6.47(d,J＝3.4Hz,1H),3.81(s,3H),2.09(s,3H).
Example (38)
1- (4-bromo-2-fluorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 550.061H NMR(400MHz,DMSO)10.63(s,1H),8.33(s,1H),7.83(d,J＝9.8Hz,1H),7.75(d,J＝8.9Hz,2H),7.71–7.65(m,1H),7.63(d,J＝8.5Hz,1H),7.50(d,J＝3.4Hz,1H),7.24(d,J＝8.9Hz,2H),7.09(s,1H),6.45(d,J＝3.4Hz,1H),3.81(s,3H),2.39(s,3H).
Example (39)
1- (3-fluorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 471.151H NMR(400MHz,DMSO)10.57(s,1H),8.26(s,1H),7.70(d,J＝8.7Hz,2H),7.61(d,J＝10.2Hz,1H),7.58–7.46(m,2H),7.43(d,J＝3.1Hz,1H),7.24(t,J＝8.5Hz,1H),7.18(d,J＝8.8Hz,2H),7.01(s,1H),6.39(d,J＝3.3Hz,1H),3.74(s,3H),2.32(s,3H).
Example (40)
4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (4-methylbenzene) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 467.181H NMR(400MHz,DMSO)10.50(s,1H),8.26(s,1H),7.69(d,J＝8.8Hz,2H),7.51(d,J＝8.3Hz,2H),7.42(d,J＝3.4Hz,1H),7.24(d,J＝8.1Hz,2H),7.17(d,J＝8.8Hz,2H),6.95(s,1H),6.38(d,J＝3.3Hz,1H),3.74(s,3H),2.31(s,3H),2.29(s,3H).
Example (41)
4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1- (2- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide (27e)
ESI-MS 521.151H NMR(400MHz,DMSO)12.11(s,1H),8.79(s,1H),8.27(s,1H),7.96(d,J＝7.7Hz,1H),7.93–7.87(m,1H),7.86–7.76(m,2H),7.70(d,J＝8.8Hz,2H),7.43(d,J＝3.2Hz,1H),7.19(d,J＝8.6Hz,2H),6.40(d,J＝3.2Hz,1H),3.74(s,3H),2.02(s,3H).
Example (42)
1- (2-chlorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 488.121H NMR(400MHz,DMSO)12.13(s,1H),8.77(s,1H),8.27(s,1H),7.72(dd,J＝15.5,8.8Hz,4H),7.62–7.51(m,2H),7.44(d,J＝3.3Hz,1H),7.19(d,J＝8.7Hz,2H),6.41(d,J＝3.1Hz,1H),3.74(s,3H),2.02(s,3H).
Example (43)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 555.141H NMR(400MHz,DMSO)12.10(s,1H),8.80(s,1H),8.27(s,1H),7.86–7.78(m,2H),7.70–7.65(m,2H),7.63–7.58(m,1H),7.49(d,J＝3.5Hz,1H),7.42(dd,J＝8.9,1.9Hz,1H),7.37(t,J＝8.6Hz,1H),6.55(d,J＝3.5Hz,1H),3.76(s,3H),2.02(s,3H).
Example (44)
1- (4-bromo-2-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 568.051H NMR(400MHz,DMSO)10.69(s,1H),8.25(s,1H),7.79–7.72(m,2H),7.64–7.54(m,2H),7.47(dd,J＝10.5,6.2Hz,2H),7.34(t,J＝8.8Hz,1H),7.03(s,1H),6.53(d,J＝3.4Hz,1H),3.75(s,3H),2.33(s,3H).
Example (45)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
ESI-MS 489.141H NMR(400MHz,DMSO)10.70(s,1H),8.26(s,1H),7.77(dd,J＝12.7,2.1Hz,1H),7.61(d,J＝10.3Hz,1H),7.54(t,J＝6.0Hz,1H),7.49(dd,J＝9.1,6.1Hz,2H),7.36(t,J＝8.8Hz,1H),7.25(t,J＝7.8Hz,1H),7.01(s,1H),6.54(d,J＝3.4Hz,1H),3.76(s,3H),2.33(s,3H).
Example (46)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-methyl-6-oxo-1- (4-methylbenzene) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 485.171H NMR(400MHz,DMSO)10.67(s,1H),8.25(s,1H),7.77(dd,J＝12.6,2.1Hz,1H),7.49(dd,J＝13.3,8.4Hz,4H),7.35(t,J＝8.8Hz,1H),7.25(d, J＝8.2Hz,2H),6.97(s,1H),6.54(d,J＝3.4Hz,1H),3.75(s,3H),2.32(s,3H),2.29(s,3H).
Example (47)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
ESI-MS 539.141H NMR(400MHz,DMSO)12.20(s,1H),8.81(s,1H),8.27(s,1H),7.97(d,J＝7.8Hz,1H),7.93–7.88(m,1H),7.87–7.77(m,3H),7.49(d,J＝3.5Hz,1H),7.42(d,J＝9.0Hz,1H),7.36(t,J＝8.6Hz,1H),6.55(d,J＝3.5Hz,1H),3.76(s,3H),2.02(s,3H).
Example (48)
1- (2-chlorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
.ESI-MS 506.111H NMR(400MHz,DMSO)12.23(s,1H),8.78(s,1H),8.27(s,1H),7.88–7.80(m,1H),7.74(dd,J＝12.4,4.7Hz,2H),7.57(tt,J＝13.1,6.6Hz,2H),7.49(d,J＝3.4Hz,1H),7.42(d,J＝9.0Hz,1H),7.37(t,J＝8.6Hz,1H),6.55(d,J＝3.5Hz,1H),3.76(s,3H),2.02(s,3H).
Example (49)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (4-methyl) -1, 4-dihydropyridazine-3-carboxamide
ESI-MS m/z:471.15
Example (50)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 4-dihydropyridazine-3-carboxamide
ESI-MS m/z:541.12
Example (51)
1- (4-bromo-2-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1, 4-dihydropyridazine-3-carboxamide
ESI-MS m/z:553.04
Example (52)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (3- (trifluoromethyl) phenyl) -1, 4-dihydropyridazine-3-carboxamide
ESI-MS m/z:525.13
Example (53)
N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (3- (trifluoromethyl) phenyl) -1, 4-dihydropyridazine-3-carboxamide
ESI-MS m/z:582.18
In vitro antitumor cell Activity
The pyrrolopyrimidine compounds containing the heteroaryl amide structure according to the formula I are screened for inhibiting the activity of lung cancer cells H460, colon cancer cells HT-29, human gastric cancer cells MKN-45, lung adenocarcinoma cells A549 and bladder cancer cells U-87MG in vitro.
(1) After cells were thawed and passaged for 2-3 stabilities, they were digested from the bottom of the flask with trypsin solution (0.25%). After pouring the cell digest into the centrifuge tube, the culture medium is added to stop the digestion. Centrifuging the centrifuge tube at 800r/min for 10min, discarding supernatant, adding 5mL culture solution, blowing and beating the mixed cells, sucking 10 μ L cell suspension, adding into cell counting plate, counting, and adjusting cell concentration to 104Per well. 100. mu.L of the cell suspension was added to the 96-well plate except that the A1 well was a blank well and no cells were added. The 96-well plate was placed in an incubator for 24 h.
(2) The test sample was dissolved in 50. mu.L of dimethyl sulfoxide, and then an appropriate amount of culture solution was added to dissolve the sample to 2mg/mL of the liquid, and then the sample was diluted to 20,4,0.8,0.16, 0.032. mu.g/mL in a 24-well plate.
3 wells were added for each concentration, two columns of cells surrounding each, which were greatly affected by the environment, and only used as blank wells. The 96-well plate was placed in an incubator for 72 h.
(3) The drug-containing culture solution in the 96-well plate is discarded, the cells are washed twice by using a phosphate buffer solution (PbS), 100 mu L of MTT (tetrazole) (0.5mg/mL) is added into each well, the MTT solution is discarded after the MTT solution is placed in an incubator for 4h, and 100 mu L of dimethyl sulfoxide is added. And oscillating on a magnetic oscillator to fully dissolve the viable cells and the MTT reaction product formazan, and putting the formazan into an enzyme labeling instrument to measure the result. Drug IC can be determined by the bliss method50The value is obtained.
The results of the compounds on inhibiting the activities of lung cancer cells H460, colon cancer cells HT-29, human gastric cancer cells MKN-45, lung adenocarcinoma cells A549 and bladder cancer cells U-87MG (see table II).
c-Met enzyme Activity assay
The assay used to measure c-Met kinase activity is based on an enzyme-linked immunosorbent assay (ELISA). The specific operation is as follows:
the example compound, 50pM c-Met (His-tagged recombinant human Met (amino acid 974-terminus), was expressed by baculovirus and 5. mu.M ATP in assay buffer (25mM MOPS, pH 7.4,5mM MgCl) on 0.25mg/mL PGT coated plates at room temperature2,0.5raM MnCl2100 μ M sodium orthovanadate, 0.01% Triton X-100, 1mM DTT, and finally DMSO concentration 1% (v/v)) for 20 minutes. The reaction mixture was removed by washing and the phosphorylated polymer substrate was detected with 0.2. mu.g/mL of a phosphotyrosine-specific monoclonal antibody (PY20) conjugated with horseradish peroxidase (HRP). After the color development was stopped by adding 1M phosphoric acid, the color of the developed substrate (TMb) was quantified spectrophotometrically at 450 nm. Data for c-Met kinase inhibition by the compounds of the examples (see table two).
Table two:
from the above test results, it is clear that the compound of formula I to be protected by the present invention has good in vitro anti-tumor activity, which is equivalent to or superior to the anti-tumor drug cisplatin on the market.
While the invention has been described with reference to specific embodiments, modifications and equivalent arrangements will be apparent to those skilled in the art and are intended to be included within the scope of the invention.
Application example 1: tablet formulation
10g of the compound of example 1 is added with 20g of auxiliary materials according to a general tabletting method in pharmacy, and the mixture is pressed into 100 tablets, wherein each tablet weighs 300 mg.
Application example 2: capsule preparation
10g of the compound in example 10 is mixed with 20g of auxiliary materials according to the requirement of a pharmaceutical capsule, and then the mixture is filled into hollow capsules, wherein each capsule weighs 300 mg.
Application example 3: injection preparation
10g of the compound obtained in example 13 was adsorbed on activated carbon by a conventional method for pharmacy, filtered through a 0.65 μm microporous membrane, and then filled in a nitrogen tank to prepare a water-injection preparation, each containing 2mL, in total, 100 bottles.
Application example 4: aerosol formulation
Dissolving 10g of the compound in example 20 in a proper amount of propylene glycol, adding distilled water and other auxiliary materials, and preparing 500mL of clear solution.
Application example 5: suppository
10g of the compound of example 19 was ground into fine powder and added with an appropriate amount of glycerin, after being ground uniformly, the mixture was added with melted glycerin gelatin, ground uniformly and poured into a mold coated with a lubricant to prepare 50 suppositories.
Application example 6: film agent
10g of the compound obtained in example 28 was dissolved by heating after swelling with stirring polyvinyl alcohol, medicinal glycerin, water, etc., and filtered through a 80-mesh screen, and the compound obtained in example 18 was dissolved by stirring in the filtrate, thereby obtaining 100 films.
Application example 7: drop pills
10g of the compound obtained in example 17 and 50g of a base such as gelatin are heated, melted and mixed uniformly, and then dropped into low-temperature liquid paraffin to obtain 1000 pills.
Application example 8: external liniment
10g of the compound of example 21 was mixed with 2.5g of an adjuvant such as an emulsifier and the like and ground by a conventional pharmaceutical method, and then distilled water was added thereto to make 200 mL.
Application example 9: ointment formulation
Prepared by grinding 10g of the compound of example 26, and then mixing with 500g of an oily base such as vaseline.
While the invention has been described with reference to specific embodiments, modifications and equivalent arrangements will be apparent to those skilled in the art and are intended to be included within the scope of the invention.

Claims (7)

1. A pyrrolopyrimidine compound containing a heteroaryl amide structure, characterized in that: the general formula is as follows:
wherein
R1Is hydrogen, (C)1-C6) Alkyl, aryl, heteroaryl, and heteroaryl,
R21-4 same or different hydrogen, fluorine, bromine and iodine;
y is O, S;
z is-Ar1-Ar2；
Ar1、Ar2Is a five-or six-membered heteroaryl group, the heteroaryl group containing 1-3 heteroatoms such as N, O, S, Ar1And Ar2Are connected to and Ar2And optionally further substituted by 1 to 3 identical or different R5Substitution;
n is 1 to 3;
R3、R4are the same or different and are each independently selected from (C)1-C6) Alkyl, (C)3-C6) A cycloalkyl group; or R3And R4Together with the nitrogen atom to which they are attached form a 5-10 membered saturated heterocyclic group, except that R3And R4Optionally containing 1 to 3 heteroatoms selected from O, N and S in addition to the attached nitrogen atom;
R51 to 3 same or different hydrogen, halogen, hydroxyl, trifluoromethyl, trifluoromethoxy, amino, azido, nitro, cyano, mercapto, (C)1-C4) Alkyl, (C)3-C6) Cycloalkyl group, (C)1-C4) Alkenyl, (C)1-C4) Alkynyl, (C)1-C4) Alkoxy group, (C)1-C4) Alkylthio, allyl, (2-methyl) allyl, (C)1-C4) Alkoxymethyl group, (C)1-C4) Alkyl acyl group, (C)1-C3) A substituent of an alkylenedioxy group.
2. A pyrrolopyrimidine compound containing a heteroaryl amide structure according to claim 1, wherein:
R1is hydrogen, methyl, ethyl,
Is composed of
n is 2 and 3;
R21-4 same or different hydrogen and fluorine;
y is O;
z is
R51 to 3 identical or different substituents selected from the group consisting of hydrogen, fluorine, chlorine, bromine, hydroxyl, trifluoromethyl, trifluoromethoxy, amino, azido, nitro, cyano, mercapto, methyl, ethyl, n-propyl, cyclopropyl, tert-butyl, vinyl, propenyl, 2-methylpropenyl, ethynyl, methoxy, ethoxy, cyclopropoxy, tert-butoxy, methylthio, ethylthio, allyl, (2-methyl) allyl, methoxymethyl, ethoxymethyl, isopropoxymethyl, formyl, acetyl, propionyl, cycloproponyl, butyryl, 2, 3-methylenedioxy, 2, 3-ethylenedioxy.
3. A pyrrolopyrimidine compound containing a heteroaryl amide structure according to claim 1, wherein: the method specifically comprises the following steps:
(1) n- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(2) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (3, 4-difluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(3) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1- (4-chlorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(4) N- (4- ((7H-phenyl [2,3-d ] pyrimidine-4-yl) oxy) phenyl-1- (4-fluorophenyl) -5-methyl-1H-1, 2, 3-triazole-4-carboxamide
(5) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5-methyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(6) N- (4- ((7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(7) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (3-chloro-4-fluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(8) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (3, 4-difluorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(9) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (4-chlorophenyl) -5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(10) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -1- (4-fluorophenyl) -5-methyl-1H-1, 2, 3-triazole-4-carboxamide
(11) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -5-methyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(12) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(13)1- (3-chloro-4-fluorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(14)1- (3, 4-difluorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(15)1- (4-chlorophenyl) -N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(16)1- (4-fluorophenyl) -5-methyl-N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1H-1, 2, 3-triazole-4-carboxamide
(17) 5-methyl-N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidine-4-yl) oxy) phenyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(18) N- (4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(19)1- (3-chloro-4-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(20)1- (3, 4-difluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(21)1- (4-chlorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1H-1,2, 3-triazole-4-carboxamide
(22)1- (4-fluorophenyl) -5-methyl-N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1H-1, 2, 3-triazole-4-carboxamide
(23) 5-methyl-N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-1-phenyl-1H-1, 2, 3-triazole-4-carboxamide
(24) N- (3-fluoro-4- ((7-methyl-7H-phenyl [2,3-d ] pyrimidin-4-yl) oxy) phenyl-5- (trifluoromethyl) -1- (2- (trifluoromethyl) phenyl) -1H-1,2, 3-triazole-4-carboxamide
(25) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(26) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(27) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(28) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(29) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-bromo-2-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(30) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (3- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(31) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(32) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(33) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(34) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(35) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (4-bromo-2-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(36) N- (4- ((7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (3- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(37) 4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(38)1- (4-bromo-2-fluorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
(39)1- (3-fluorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
(40) 4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(41) 4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1- (2- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide (27e)
(42)1- (2-chlorophenyl) -4-methyl-N- (4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -6-oxo-1, 6-dihydropyridazine-3-carboxamide
(43) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(44)1- (4-bromo-2-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(45) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -1- (3-fluorophenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(46) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (4-benzyl) -1, 6-dihydropyridazine-3-carboxamide
(47) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1- (2- (trifluoromethyl) phenyl) -1, 6-dihydropyridazine-3-carboxamide
(48)1- (2-chlorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4 yl-oxy) phenyl) -4-methyl-6-oxo-1, 6-dihydropyridazine-3-carboxamide
(49) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (4-methyl) -1, 4-dihydropyridazine-3-carboxamide
(50) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (2- (trifluoromethoxy) phenyl) -1, 4-dihydropyridazine-3-carboxamide
(51)1- (4-bromo-2-fluorophenyl) -N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1, 4-dihydropyridazine-3-carboxamide
(52) N- (3-fluoro-4- ((7-methyl-7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) phenyl) -4-oxo-1- (3- (trifluoromethyl) phenyl) -1, 4-dihydropyridazine-3-carboxamide
(53) N- (4- ((7- (2- (dimethylamine) ethyl) -7H-pyrrolo [2,3-d ] pyrimidin-4-yl) oxy) -3-fluorophenyl) -4-oxo-1- (3- (trifluoromethyl) phenyl) -1, 4-dihydropyridazine-3-carboxamide.
4. A pharmaceutical composition comprising a compound of any one of claims 1 to 3, and a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof as an active ingredient together with a pharmaceutically acceptable excipient.
5. The use of a compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition of claim 4, for the manufacture of a medicament for the treatment and/or prevention of a proliferative disease.
6. Use of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition according to claim 4, for the manufacture of a medicament for the treatment and/or prophylaxis of cancer.
7. Use of a compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition of claim 4, for the manufacture of a medicament for the treatment and/or prophylaxis of lung cancer, liver cancer, gastric cancer, colon cancer, breast cancer.
CN201710593543.2A 2017-04-14 2017-07-20 The preparation and application of the Pyrrolopyrimidine compounds of the structure containing heteroaryl amide Pending CN107383016A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017102480721 2017-04-14
CN201710248072 2017-04-14

Publications (1)

Publication Number Publication Date
CN107383016A true CN107383016A (en) 2017-11-24

Family

ID=60337250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710593543.2A Pending CN107383016A (en) 2017-04-14 2017-07-20 The preparation and application of the Pyrrolopyrimidine compounds of the structure containing heteroaryl amide

Country Status (1)

Country Link
CN (1) CN107383016A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948014A (en) * 2018-08-24 2018-12-07 江西科技师范大学 1- aryl -4- Oxy-1, the preparation and application of the pyrido heterocycle compound of 4- dihydroquinoline structure
CN110407839A (en) * 2019-07-01 2019-11-05 江西科技师范大学 The preparation and application of the triazol heterocycle compound of the structure containing heteroaryl amide
CN110467616A (en) * 2019-07-01 2019-11-19 江西科技师范大学 Replace the preparation and application of the Triazolopyrazine class compound of pyridazinone structure containing heteroaryl
CN110642837A (en) * 2019-11-07 2020-01-03 江西科技师范大学 Pyridine amide compound containing triazole or quinolinone structure and application thereof
CN113087709A (en) * 2020-01-09 2021-07-09 沈阳药科大学 Pyrrolopyrimidine derivatives, and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296928A (en) * 2005-10-28 2008-10-29 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
CN102464667A (en) * 2010-11-03 2012-05-23 中国科学院上海药物研究所 Five-membered heterocyclic pyrimidine compounds, preparation method and application thereof
CN106467541A (en) * 2015-08-18 2017-03-01 暨南大学 Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application
CN106543145A (en) * 2016-10-28 2017-03-29 山西医科大学 C Met kinases suppression 5 benzoic acid amides derivant of agent 3 (4 fluorophenyl) pyrimidone, preparation method and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296928A (en) * 2005-10-28 2008-10-29 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
CN102464667A (en) * 2010-11-03 2012-05-23 中国科学院上海药物研究所 Five-membered heterocyclic pyrimidine compounds, preparation method and application thereof
CN106467541A (en) * 2015-08-18 2017-03-01 暨南大学 Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application
CN106543145A (en) * 2016-10-28 2017-03-29 山西医科大学 C Met kinases suppression 5 benzoic acid amides derivant of agent 3 (4 fluorophenyl) pyrimidone, preparation method and application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI TAN,等: "4‑Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
WEI ZHANG, 等: "Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold", 《MOLECULES》 *
WEI ZHANG, 等: "Discovery of novel type II c-Met inhibitors based on BMS-777607", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948014A (en) * 2018-08-24 2018-12-07 江西科技师范大学 1- aryl -4- Oxy-1, the preparation and application of the pyrido heterocycle compound of 4- dihydroquinoline structure
CN110407839A (en) * 2019-07-01 2019-11-05 江西科技师范大学 The preparation and application of the triazol heterocycle compound of the structure containing heteroaryl amide
CN110467616A (en) * 2019-07-01 2019-11-19 江西科技师范大学 Replace the preparation and application of the Triazolopyrazine class compound of pyridazinone structure containing heteroaryl
CN110407839B (en) * 2019-07-01 2022-01-04 江西科技师范大学 Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure
CN110642837A (en) * 2019-11-07 2020-01-03 江西科技师范大学 Pyridine amide compound containing triazole or quinolinone structure and application thereof
CN113087709A (en) * 2020-01-09 2021-07-09 沈阳药科大学 Pyrrolopyrimidine derivatives, and preparation method and application thereof

Similar Documents

Publication Publication Date Title
US11352341B2 (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
US9487529B2 (en) Macrocyclic compounds as ALK, FAK and JAK2 inhibitors
JP6087954B2 (en) Quinolines and cinnolines compounds and uses thereof
CN107383016A (en) The preparation and application of the Pyrrolopyrimidine compounds of the structure containing heteroaryl amide
JP6896701B2 (en) Imidazolylamide derivative
JP3763414B2 (en) Crystal form of N- {2-chloro-4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} -N '-(5-methyl-3-isoxazolyl) urea salt
CN108314682A (en) The preparation and application of the miscellaneous quinolines of the disubstituted -4- virtues of 6,7-
JP2019518776A (en) Crystals of Aniline Pyrimidine Compounds as EGFR Inhibitors
CN108329258B (en) Semicarbazone structure-containing 4-phenoxypyridine derivative and application thereof
CN107573340B (en) Preparation and application of 2-carbamoyl-4-aryl hetero pyridine compound
CN110563697A (en) preparation and application of 2-pyridine carboxamide compound
CN107253964A (en) The preparation and application of the thienopyrimidines of the structure containing heteroaryl amide
CN107151233B (en) Hydrazone-containing pyrimidine derivative and application thereof
WO2016023330A1 (en) Quinazoline derivative
CN110467616B (en) Preparation and application of triazolopyrazine compound containing heteroaryl substituted pyridazinone structure
JP2021529175A (en) Crystal form of CDK4 / 6 activity inhibitor compound and its use
CN110642837B (en) Pyridine amide compound containing triazole or quinolinone structure and application thereof
WO2021121146A1 (en) Crystal form a of aminopyrimidine mesylate compound, preparation method therefor, and application thereof
CN110407839B (en) Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure
CN104211682B (en) Pyridine compounds and their and application thereof
CN107474039A (en) Ketone containing triazole and the 4- phenoxy groups substituted quinoline derivatives of imidazoles and its application
CN103965107B (en) 2-aryl substituted quinoline derivatives and application thereof
US20230322687A1 (en) Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof
CN112047941B (en) Compound and application thereof in preparing medicine for treating diseases caused by high expression of Flt3/c-Met kinase
CN105017217A (en) Pyrazolone-containing quinoline compound and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171124